BioSpace News Archive

BioCapital

Genworth’s Beyond Dollars Study 2018 Reveals Caregivers Are Getting Younger; Stress, Mental Health Issues Continue Unabated

Caregivers in the United States are getting younger and continue to struggle with stress and depression, no matter what their age, according to Genworth’s Beyond Dollars Study 20181 released today.

November 13, 2018
·
7 min read
Pharm Country

Holistic Dentist Pens a Modern Approach to Oral Health

Dr. Nammy Patel Releases “Age with Style: Your Guide to a Youthful Smile & Healthy Living” with ForbesBooks

November 13, 2018
·
2 min read
Drug Development

Palvella Therapeutics Announces FDA Fast Track Designation for PTX-022 for Treatment of Pachyonychia Congenita

Palvella Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PTX-022.

November 13, 2018
·
4 min read
Drug Development

First patient Enrolled in Pivotal Clinical Phase 3 Study NEFIGARD with Lead Candidate Nefecon

Calliditas Therapeutics AB today announced that the first patient has been enrolled in the company’s pivotal clinical phase 3 study NEFIGARD in patients with IgA nephropathy (IgAN).

November 13, 2018
·
4 min read
Union Bridge Holdings Signs MOU with APrevent Medical Inc.

Union Bridge Holdings Limited has signed a Memorandum of Understanding (“MOU”) with APrevent Medical Inc. (“APrevent”) regarding a potential share swap between UGHL and APrevent.

November 13, 2018
·
3 min read
Policy

The governments of Canada and Saskatchewan improve access to treatment for people with substance use disorders

The opioid crisis continues to devastate individuals, families and communities across the country. Without increased access to effective, evidence-based treatment options, people with substance use disorder will continue to be at risk for overdose.

November 13, 2018
·
3 min read
Drug Development

AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis

EXPEDITION-8 is the first Phase 3b study evaluating 8 weeks of MAVYRET™ in treatment-naïve chronic hepatitis C virus (HCV)-infected patients with compensated cirrhosis across all major genotypes (GT1-6)[1]

November 13, 2018
·
8 min read
Business

International Isotopes Inc. Announces a Long-Term Supply Agreement For I-131 With The University Of Missouri Research Reactor

INIS Will Utilize The Sole Domestic Producer As One Of Their Principal Suppliers Of This Important Isotope

November 13, 2018
·
3 min read
Biotech Bay

Omada Program for Underserved Participants Delivers Strong Results

Study of Adapted Omada Program Demonstrates Strong Engagement and Weight Loss

November 13, 2018
·
4 min read
Genetown

Enanta Announces that AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis

EXPEDITION-8 is the first Phase 3b study evaluating 8 weeks of MAVYRET™ in treatment-naïve chronic hepatitis C virus (HCV)-infected patients with compensated cirrhosis across all major genotypes (GT1-6)1

November 13, 2018
·
9 min read